18/04/2014 09:44:16 Free Membership Login

XenoPort to Present at the RBC Capital Markets' Healthcare Conference

Date : 02/23/2012 @ 1:00PM
Source : Business Wire
Stock : Xenoport, Inc. (MM) (XNPT)
Quote : 4.2  0.02 (0.48%) @ 8:10PM
Xenoport, Inc. (MM) share price Chart

XenoPort to Present at the RBC Capital Markets' Healthcare Conference

Xenoport, Inc. (MM) (NASDAQ:XNPT)
Historical Stock Chart

3 Years : From Apr 2011 to Apr 2014

Click Here for more Xenoport, Inc. (MM) Charts.

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the RBC Capital Markets' Healthcare Conference. The live presentation will occur at 11:00 a.m. Pacific Time (2:00 p.m. Eastern Time) on Wednesday, February 29, 2012. A replay of the presentation will also be available.

To access the live presentation via the Web, please go to www.XenoPort.com. Please connect to the Website at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the Webcast.

A replay of the Webcast can be accessed for a minimum of one week and will be available approximately 24 hours after the live presentation.

About XenoPort

XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is XenoPort’s first U.S. Food and Drug Administration-approved product. GlaxoSmithKline currently holds commercialization rights and certain development rights for gabapentin enacarbil in the United States. Regnite® (gabapentin enacarbil) is approved for the treatment of moderate-to-severe primary restless legs syndrome in Japan. Astellas Pharma Inc. holds all development and commercialization rights for Regnite in Japan and gabapentin enacarbil in five Asian countries. XenoPort holds all other world-wide rights and has co-promotion and certain development rights to gabapentin enacarbil in the United States. XenoPort’s pipeline of product candidates includes potential treatments for patients with postherpetic neuralgia, spasticity and Parkinson’s disease.

To learn more about XenoPort, please visit the Website at www.XenoPort.com.

XENOPORT is a registered trademark of XenoPort, Inc.

Horizant is a registered trademark of GlaxoSmithKline.

Regnite is a registered trademark of Astellas Pharma Inc.

XNPT2G



NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us 140418 09:44